ArticleNeurology2022
Headache, Opiate Use, and Prescribing Trends in Women With Idiopathic Intracranial Hypertension: A Population-Based Matched Cohort Study.
Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension.Brain : a journal of neurology · 2026Trial
- Identifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension: A Pilot Study.Neurology · 2026Trial
- CGRP-provoked headache is associated with a neuroimmune signature in idiopathic intracranial hypertension.The journal of headache and pain · 2026Trial
- Article
- Hyperandrogenism and polycystic ovary syndrome phenotypes in idiopathic intracranial hypertension.Irish journal of medical science · 2026Article
- A call to develop rigorous standards for excellence in idiopathic intracranial hypertension: RISE-IIH.Eye (London, England) · 2026Article
- Epidemiology, pharmacological treatment and invasive management of idiopathic intracranial hypertension in Austria: a nationwide, hospital-based, controlled analysis of insurance data.The journal of headache and pain · 2026Article
- Longitudinal visual outcomes in idiopathic intracranial hypertension: the role of early prognostic indicators and risk stratification in disease management.Journal of neurology · 2025Article
- Managing idiopathic intracranial hypertension in the eye clinic.Eye (London, England) · 2024Review
- Progress and recognition of idiopathic intracranial hypertension: A narrative review.CNS neuroscience & therapeutics · 2024Review
- Does a Healthy Weight Body Mass Index at Onset of Idiopathic Intracranial Hypertension Change the Outcomes? A United Kingdom Prospective Cohort Study.Neuro-ophthalmology (Aeolus Press) · 2024Article
- The Pressure of Headache at the United Kingdom CSF Disorders Day 2023.Neuro-ophthalmology (Aeolus Press) · 2024Article
- Longitudinal prospective cohort study evaluating prognosis in idiopathic intracranial hypertension patients with and without comorbid polycystic ovarian syndrome.Eye (London, England) · 2023Article
- Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms.Nature reviews. Neurology · 2023Review
- Overlap and Differences in Migraine and Idiopathic Intracranial Hypertension.Current pain and headache reports · 2023Review
- Comment on: 'The expanding spectrum of idiopathic intracranial hypertension'.Eye (London, England) · 2023Article
- Co-morbid Polycystic Ovarian Syndrome with Idiopathic Intracranial Hypertension.Neuro-ophthalmology (Aeolus Press) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
BACKGROUND AND
objectivesPhysician prescribing habits for opiates and headache therapies have not been previously evaluated in a large, matched cohort study in idiopathic intracranial hypertension (IIH). Our objective was to evaluate opiate and headache medication prescribing habits in women with IIH compared with matched women with migraine and population controls. We also investigated the occurrence of new onset headache in IIH compared with population controls.
methodsWe performed a population-based matched, retrospective cohort study to explore headache outcomes. Cross-sectional analyses were used to describe medication prescribing patterns. We used data from IQVIA Medical Research Data, an anonymized, nationally representative primary care electronic medical record database in the United Kingdom, from January 1, 1995, to September 25, 2019. Women aged 16 years and older were eligible for inclusion. Women with IIH (exposure) were matched by age and body mass index with up to 10 control women without IIH but with migraine (migraine controls), and without IIH or migraine (population controls).
resultsA total of 3,411 women with IIH, 13,966 migraine controls, and 33,495 population controls were included. The adjusted hazard ratio for new onset headache in IIH compared with population controls was 3.09 (95% CI 2.78-3.43). In the first year after diagnosis, 58% of women with IIH were prescribed acetazolamide and 20% topiramate. In total, 20% of women with IIH were prescribed opiates within the first year of their diagnosis, reducing to 17% after 6 years, compared with 8% and 11% among those with migraine, respectively. Twice as many women with IIH were prescribed opiates compared with migraine controls, and 3 times as many women with IIH were prescribed opiates compared with population controls. Women with IIH were also prescribed more headache preventative medications compared with migraine controls. DISCUSSION: Women with IIH were more likely to be prescribed opiate and simple analgesics compared with both migraine and population controls. Women with IIH trialed more preventative medications over their disease course suggesting that headaches in IIH may be more refractory to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.